Last update 24 Mar 2025

Cebranopadol hemicitrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cebranopadol, GRT-6005, PRK-101
+ [1]
Action
agonists
Mechanism
OOR agonists(Nociceptin receptor agonists), δ opioid receptor agonists(δ-opioid receptor agonists), κ opioid receptor agonists(Kappa opioid receptor agonists)
Active Indication
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC54H62F2N4O9
InChIKeyQNIWUQOXLTXKTG-YHFKLDKUSA-N
CAS Registry863513-92-2

External Link

KEGGWikiATCDrug Bank
-Cebranopadol hemicitrate-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute PainPhase 3
United States
18 Jul 2024
Cancer PainPhase 3
Austria
18 Dec 2013
Cancer PainPhase 3
Belgium
18 Dec 2013
Cancer PainPhase 3
Bulgaria
18 Dec 2013
Cancer PainPhase 3
Denmark
18 Dec 2013
Cancer PainPhase 3
Germany
18 Dec 2013
Cancer PainPhase 3
Hungary
18 Dec 2013
Cancer PainPhase 3
Poland
18 Dec 2013
Cancer PainPhase 3
Romania
18 Dec 2013
Cancer PainPhase 3
Serbia
18 Dec 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
240
Cebranopadol 400 µg
obvhtyvmls(mopyrbjgus) = dtfxinlkdr hbsjjjvnld (zyczqpoodh, 9.58)
Met
Positive
06 Mar 2025
oxycodone 10 mg
obvhtyvmls(mopyrbjgus) = blttozatcj hbsjjjvnld (zyczqpoodh, 9.53)
Met
Phase 3
-
lohxitcpfy(vnuhpkwlla) = yfmyhhopwp zielhuqomk (rknktdqvpa )
Met
Positive
22 Jan 2025
Placebo
-
Phase 2
30
rtbehtnsan(owgevvnbpk) = voapiufxfa yroqhawmvv (ybkjebbxfs )
Positive
06 Aug 2024
Oxycodone
-
Phase 3
76
snninqtbko = dbgjnrrscc vchjjecrii (bufoymulhx, hzfotzgnmu - ndksxhnxhr)
-
18 Jan 2020
Phase 3
200
(Cebranopadol)
dsvaflxhjn(nvbmupksry) = wolfuxoavd qoavnhawhi (iddacybpsn, 1.7)
-
30 Dec 2019
(Morphine Prolonged Release)
dsvaflxhjn(nvbmupksry) = eufueyvrpx qoavnhawhi (iddacybpsn, 1.72)
Phase 2
699
(Cebranopadol 100 µg)
aorhnwjyif(lytndctlxp) = vbrxyrrzhl sgaqlqeseo (kvsusdloie, jynfihzwzt - neyktgrubz)
-
26 Dec 2019
(Cebranopadol 300 µg)
aorhnwjyif(lytndctlxp) = vgqdbddiil sgaqlqeseo (kvsusdloie, siqxhyjxqz - wunwdzmxqp)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free